{"disease":{"id":"aml-childhood","name":"aml childhood"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06158828","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06389357","title":"Retun-to-school Adaptation Program for Children With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Gazi University","has_results":false},{"nct_id":"NCT06326463","title":"CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03825367","title":"Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":13,"lead_sponsor_name":"Therapeutic Advances in Childhood Leukemia Consortium","has_results":false},{"nct_id":"NCT04326439","title":"AflacLL1901 (CHOA-AML)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT05077423","title":"A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Y-mAbs Therapeutics","has_results":false},{"nct_id":"NCT05622591","title":"ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Elucida Oncology","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}